Empyema Treated With tPA & DNAse

Withdrawn before enrolling · Phase 3

Conditions studied: Empyema

In brief

The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA. The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse. The primary outcome variable between the two techniques will be length of hospitalization after initiation of treatment.

Key facts

Study ID

NCT01862458

Run by

Children's Mercy Hospital Kansas City

People needed

0

Starts

2016-01-01

Expected to finish

2016-01-01

Last updated by the study team

2016-01-28

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients less than 18 years of age requiring an intervention for empyema by one of the following:
• Septation or loculation seen on ultrasound or computed tomography or
• Greater than 10,000 white blood cells identified on pleural tap

You may not qualify if…

• Immunodeficiency process
• Secondary diagnosis or condition that will keep them in the hospital beyond the empyema
• Existing contraindications to chest tube
• Documented allergy to one of the study medications

Where it is running

• Children's Mercy Hospital — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.